Apoptosis

, Volume 10, Issue 3, pp 583–595 | Cite as

Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis

  • G. Gu
  • T. A. Hentunen
  • M. Nars
  • P. L. Härkönen
  • H. K. Väänänen
Article

Abstract

Glucocorticoid-induced osteoporosis may be at least in part due to the increased apoptosis of osteocytes. To study the role of osteocyte apoptosis in glucocorticoid-induced osteoporosis, we isolated primary osteocytes from murine calvaria for the analysis of the effects of dexamethasone in in vitro culture. The cells were identified by morphology, cytochemical staining, immunocytochemical staining and mRNA expression of phosphate-regulating gene with homology to endopeptidases on the X chromosome (PHEX) and sclerosteosis/van Buchem disease gene (SOST). We found that dexamethasone induced osteocyte apoptosis in a dose-dependent manner. A glucocorticoid receptor antagonist, mifepristone (RU486), suppressed dexamethasone-induced osteocyte apoptosis, suggesting that it was mediated by glucocorticoid receptor. Immunocytochemical stainings showed that glucocorticoid receptors are present in primary osteocytes, and they were translocated to nuclei after the exposure to dexamethasone. Addition of estrogen prevented glucocorticoid receptor translocation into nuclei. Corresponding antiapoptotic effects in primary osteocytes were also seen after the pretreatment of primary osteocytes with a picomolar concentration of estrogen. The pure antiestrogen ICI 182,780 inhibited estrogen effect on apoptosis induced by dexamethasone. These data suggest that glucocorticoid receptors play an important role in glucocorticoid-induced osteocyte apoptosis. Most importantly, estrogen has a protective effect {against osteocyte}{ }{apoptosis}. To conclude, the mechanism of glucocorticoid-induced osteoporosis may be due to the apoptosis of osteocytes, which can be opposed by estrogen.

Keywords

apoptosis estrogen glucocorticoid osteocyte osteoporosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vaananen KH, Harkonen PL. Bone effects of glucocorticoid therapy. Ernst Schering Res Found Workshop 2002; 40: 55–64.PubMedGoogle Scholar
  2. 2.
    Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 2002; 966: 73–81.PubMedGoogle Scholar
  3. 3.
    Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15(6): 993–1000.PubMedGoogle Scholar
  4. 4.
    Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 1992; 326(22): 1473–1479.PubMedGoogle Scholar
  5. 5.
    Amsterdam A, Sasson R. The anti-inflammatory action of glucocorticoids is mediated by cell type specific regulation of apoptosis. Mol Cell Endocrinol 2002; 189(12): 1–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Gustafsson JA, Carlstedt-Duke J, Poellinger L, et al. Biochemistry, molecular biology, and physiology of the glucocorticoid receptor. Endocr Rev 1987; 8(2): 185–234.PubMedGoogle Scholar
  7. 7.
    Reichardt HM, Tronche F, Berger S, Kellendonk C, Schutz G. New insights into glucocorticoid and mineralocorticoid signaling: Lessons from gene targeting. Adv Pharmacol 2000; 47: 1–21.PubMedGoogle Scholar
  8. 8.
    Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE. The localization of the functional glucocorticoid receptor alpha in human bone. J Clin Endocrinol Metab 2000; 85(2): 883–889.CrossRefPubMedGoogle Scholar
  9. 9.
    Beavan S, Horner A, Bord S, Ireland D, Compston J. Colocalization of glucocorticoid and mineralocorticoid receptors in human bone. J Bone Miner Res 2001; 16(8): 1496–1504.PubMedGoogle Scholar
  10. 10.
    Weinstein RS. Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2001; 2(1): 65–73.CrossRefPubMedGoogle Scholar
  11. 11.
    Pereira RM, Delany AM, Canalis E. Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone 2001; 28(5): 484–490.CrossRefPubMedGoogle Scholar
  12. 12.
    Zalavras C, Shah S, Birnbaum MJ, Frenkel B. Role of apoptosis in glucocorticoid-induced osteoporosis and osteonecrosis. Crit Rev Eukaryot Gene Expr 2003; 13(2–4): 221–235.CrossRefPubMedGoogle Scholar
  13. 13.
    Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102(2): 274–282.PubMedGoogle Scholar
  14. 14.
    Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 2000; 85(8): 2907–2912.CrossRefPubMedGoogle Scholar
  15. 15.
    Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104(10): 1363–1374.PubMedGoogle Scholar
  16. 16.
    Jande SS, Belanger LF. The life cycle of the osteocyte. Clin Orthop 1973; 94: 281–305.PubMedGoogle Scholar
  17. 17.
    Jones SJ, Gray C, Sakamaki H, et al. The incidence and size of gap junctions between the bone cells in rat calvaria. Anat Embryol (Berl) 1993; 187(4): 343–352.Google Scholar
  18. 18.
    Aarden EM, Burger EH, Nijweide PJ. Function of osteocytes in bone. J Cell Biochem 1994; 55(3): 287–299.PubMedGoogle Scholar
  19. 19.
    Burger EH, Klein-Nulend J. Mechanotransduction in bone—role of the lacuno-canalicular network. Faseb J 1999; 13(Suppl): S101–S112.PubMedGoogle Scholar
  20. 20.
    Lanyon LE. Osteocytes, strain detection, bone modeling and remodeling. Calcif Tissue Int 1993; 53(Suppl 1): S102–S106; discussion S106–S107.CrossRefPubMedGoogle Scholar
  21. 21.
    Mikuni-Takagaki Y. Mechanical responses and signal transduction pathways in stretched osteocytes. J Bone Miner Metab 1999; 17(1): 57–60.CrossRefPubMedGoogle Scholar
  22. 22.
    Skerry TM, Bitensky L, Chayen J, Lanyon LE. Early strain-related changes in enzyme activity in osteocytes following bone loading in vivo. J Bone Miner Res 1989; 4(5): 783–788.PubMedGoogle Scholar
  23. 23.
    Ajubi NE, Klein-Nulend J, Alblas MJ, Burger EH, Nijweide PJ. Signal transduction pathways involved in fluid flow-induced PGE2 production by cultured osteocytes. Am J Physiol 1999; 276(1 Pt 1): E171–E178.PubMedGoogle Scholar
  24. 24.
    Cherian PP, Cheng B, Gu S, Sprague E, Bonewald LF, Jiang JX. Effects of mechanical strain on the function of Gap junctions in osteocytes are mediated through the prostaglandin EP2 receptor. J Biol Chem 2003; 278(44): 43146–43156.CrossRefPubMedGoogle Scholar
  25. 25.
    Klein-Nulend J, Semeins CM, Ajubi NE, Nijweide PJ, Burger EH. Pulsating fluid flow increases nitric oxide (NO) synthesis by osteocytes but not periosteal fibroblasts—correlation with prostaglandin upregulation. Biochem Biophys Res Commun 1995; 217(2): 640–648.CrossRefPubMedGoogle Scholar
  26. 26.
    Dodd JS, Raleigh JA, Gross TS. Osteocyte hypoxia: A novel mechanotransduction pathway. Am J Physiol 1999; 277(3 Pt 1): C598–C602.PubMedGoogle Scholar
  27. 27.
    Mason DJ, Suva LJ, Genever PG, et al. Mechanically regulated expression of a neural glutamate transporter in bone: A role for excitatory amino acids as osteotropic agents? Bone 1997; 20(3): 199–205.CrossRefPubMedGoogle Scholar
  28. 28.
    Huggett JF, Mustafa A, O’Neal L, Mason DJ. The glutamate transporter GLAST-1 (EAAT-1) is expressed in the plasma membrane of osteocytes and is responsive to extracellular glutamate concentration. Biochem Soc Trans 2002; 30(Pt 6): 890–893.CrossRefPubMedGoogle Scholar
  29. 29.
    Turner CH, Robling AG, Duncan RL, Burr DB. Do bone cells behave like a neuronal network? Calcif Tissue Int 2002; 70(6): 435–442.CrossRefPubMedGoogle Scholar
  30. 30.
    Heino TJ, Hentunen TA, Vaananen HK. Osteocytes inhibit osteoclastic bone resorption through transforming growth factor-beta: Enhancement by estrogen. J Cell Biochem 2002; 85(1): 185–197.CrossRefPubMedGoogle Scholar
  31. 31.
    Heino TJ, Hentunen TA, Vaananen HK. Conditioned medium from osteocytes stimulates the proliferation of bone marrow mesenchymal stem cells and their differentiation into osteoblasts. Exp Cell Res 2004; 294 (2): 458–468.CrossRefPubMedGoogle Scholar
  32. 32.
    Noble BS, Stevens H, Loveridge N, Reeve J. Identification of apoptotic changes in osteocytes in normal and pathological human bone. Bone 1997; 20(3): 273–282.CrossRefPubMedGoogle Scholar
  33. 33.
    Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999; 14(7): 1061–1066.PubMedGoogle Scholar
  34. 34.
    Wong G, Cohn DV. Separation of parathyroid hormone and calcitonin-sensitive cells from non-responsive bone cells. Nature 1974; 252(5485): 713–715.PubMedGoogle Scholar
  35. 35.
    Hefley TJ. Utilization of FPLC-purified bacterial collagenase for the isolation of cells from bone. J Bone Miner Res 1987; 2(6): 505–516.PubMedGoogle Scholar
  36. 36.
    Spitz IM, Bardin CW. Mifepristone (RU 486)–a modulator of progestin and glucocorticoid action. N Engl J Med 1993; 329(6): 404–412.PubMedGoogle Scholar
  37. 37.
    Sambrook PN, Hughes DR, Nelson AE, Robinson BG, Mason RS. Osteocyte viability with glucocorticoid treatment: Relation to histomorphometry. Ann Rheum Dis 2003; 62(12): 1215–1217.PubMedGoogle Scholar
  38. 38.
    O’Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004; 145(4): 1835–1841.PubMedGoogle Scholar
  39. 39.
    Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 2001; 16(1): 97–103.PubMedGoogle Scholar
  40. 40.
    Eberhardt AW, Yeager-Jones A, Blair HC. Regional trabecular bone matrix degeneration and osteocyte death in femora of glucocorticoid- treated rabbits. Endocrinology 2001; 142(3): 1333–1340.PubMedGoogle Scholar
  41. 41.
    Tomkinson A, Gevers EF, Wit JM, Reeve J, Noble BS. The role of estrogen in the control of rat osteocyte apoptosis. J Bone Miner Res 1998; 13(8): 1243–1250.PubMedGoogle Scholar
  42. 42.
    Peck WA, Birge SJ, Jr., Fedak SA. Bone Cells: Biochemical and Biological Studies after Enzymatic Isolation. Science 1964; 146: 1476–1477.PubMedGoogle Scholar
  43. 43.
    Giguere V, Hollenberg SM, Rosenfeld MG, Evans RM. Functional domains of the human glucocorticoid receptor. Cell 1986; 46(5): 645–652.PubMedGoogle Scholar
  44. 44.
    Sanchez ER, Hirst M, Scherrer LC, et al. Hormone-free mouse glucocorticoid receptors overexpressed in Chinese hamster ovary cells are localized to the nucleus and are associated with both hsp70 and hsp90. J Biol Chem 1990; 265(33): 20123–20130.PubMedGoogle Scholar
  45. 45.
    Bamberger CM, Bamberger AM, de Castro M, Chrousos GP. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995; 95(6): 2435–2441.PubMedGoogle Scholar
  46. 46.
    Beato M. Gene regulation by steroid hormones. Cell 1989; 56(3): 335–344.CrossRefPubMedGoogle Scholar
  47. 47.
    Oakley RH, Sar M, Cidlowski JA. The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. J Biol Chem 1996; 271(16): 9550–9559.PubMedGoogle Scholar
  48. 48.
    Shoupe D, Mishell DR, Jr., Lahteenmaki P, et al. Effects of the antiprogesterone RU 486 in normal women. I. Single-dose administration in the midluteal phase. Am J Obstet Gynecol 1987; 157(6): 1415–1420.PubMedGoogle Scholar
  49. 49.
    Sasson R, Tajima K, Amsterdam A. Glucocorticoids protect against apoptosis induced by serum deprivation, cyclic adenosine 3′,5′-monophosphate and p53 activation in immortalized human granulosa cells: Involvement of Bcl-2. Endocrinology 2001; 142(2): 802–811.PubMedGoogle Scholar
  50. 50.
    Jenkins BD, Pullen CB, Darimont BD. Novel glucocorticoid receptor coactivator effector mechanisms. Trends Endocrinol Metab 2001; 12(3): 122–126.PubMedGoogle Scholar
  51. 51.
    Schmidt M, Lugering N, Lugering A, et al. Role of the CD95/CD95 ligand system in glucocorticoid-induced monocyte apoptosis. J Immunol 2001; 166(2): 1344–1351.PubMedGoogle Scholar
  52. 52.
    Laman JD, Claassen E, Noelle RJ. Functions of CD40 and its ligand, gp39 (CD40L). Crit Rev Immunol 1996; 16(1): 59–108.PubMedGoogle Scholar
  53. 53.
    Ahuja SS, Zhao S, Bellido T, Plotkin LI, Jimenez F, Bonewald LF. CD40 ligand blocks apoptosis induced by tumor necrosis factor alpha, glucocorticoids, and etoposide in osteoblasts and the osteocyte-like cell line murine long bone osteocyte-Y4. Endocrinology 2003; 144(5): 1761–1769.PubMedGoogle Scholar
  54. 54.
    Gohel A, McCarthy MB, Gronowicz G. Estrogen prevents glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro. Endocrinology 1999; 140(11): 5339–5347.PubMedGoogle Scholar
  55. 55.
    Krishnan AV, Swami S, Feldman D. Estradiol inhibits glucocorticoid receptor expression and induces glucocorticoid resistance in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol 2001; 77(1): 29–37.PubMedGoogle Scholar
  56. 56.
    Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138(3): 863–870.Google Scholar
  57. 57.
    Sibonga JD, Dobnig H, Harden RM, Turner RT. Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia. Endocrinology 1998; 139(9): 3736–3742.PubMedGoogle Scholar
  58. 58.
    Turner RT, Evans GL, Dobnig H. The high-affinity estrogen receptor antagonist ICI 182,780 has no effect on bone growth in young male rats. Calcif Tissue Int 2000; 66(6): 461–464.PubMedGoogle Scholar
  59. 59.
    Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992; 7(9): 1063–1069.PubMedGoogle Scholar
  60. 60.
    Rhen T, Grissom S, Afshari C, Cidlowski JA. Dexamethasone blocks the rapid biological effects of 17beta-estradiol in the rat uterus without antagonizing its global genomic actions. Faseb J 2003; 17(13): 1849–1870.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • G. Gu
    • 1
  • T. A. Hentunen
    • 1
  • M. Nars
    • 1
  • P. L. Härkönen
    • 1
  • H. K. Väänänen
    • 1
    • 2
  1. 1.Department of Anatomy, Institute of BiomedicineUniversity of TurkuTurkuFinland
  2. 2.TurkuFinland

Personalised recommendations